| Entry |
|
| Name |
Avutometinib potassium (USAN) |
| Formula |
C21H17FN5O5S. K
|
| Exact mass |
509.0571
|
| Mol weight |
509.55
|
| Structure |

|
| Class |
Antineoplastic
DG03137 MEK inhibitor
|
| Remark |
| Product (mixture): | D13120<US> |
|
| Efficacy |
Antineoplastic, Tyrosine kinase inhibitor |
| Target |
|
| Pathway |
|
| Brite |
Drug groups [BR:br08330]
Antineoplastic
DG03137 MEK inhibitor
DG03255 Avutometinib
D12534 Avutometinib potassium
Target-based classification of drugs [BR:br08310]
Protein kinases
Serine/threonine kinases
STE group
MAP2K (MEK)
D12534 Avutometinib potassium (USAN)
TKL group
RAF1
D12534 Avutometinib potassium (USAN)
Drug groups [BR:br08330]
Antineoplastic
DG03137 MEK inhibitor
DG03255 Avutometinib
|
| Other DBs |
|
| LinkDB |
|
| KCF data |
ATOM 34
1 C8x C 8.9075 -14.5884
2 C8x C 8.9075 -15.9911
3 C8x C 10.0998 -16.6924
4 N5x N 11.3622 -15.9911
5 C8y C 11.3622 -14.5884
6 N5x N 10.0998 -13.8870
7 O2a O 12.5545 -13.8870
8 C8y C 13.8170 -14.5884
9 C8x C 13.8170 -15.9911
10 C8x C 15.0093 -16.6924
11 C8y C 16.2016 -15.9911
12 C8y C 16.2016 -14.5884
13 C8x C 15.0093 -13.8870
14 C8y C 17.4641 -16.6924
15 C8y C 18.6564 -15.9911
16 C8y C 18.6564 -14.5884
17 O7x O 17.4641 -13.8870
18 C1b C 19.8487 -16.6924
19 C8y C 21.1112 -15.9911
20 O6a O 19.8487 -13.8870
21 C1a C 17.4641 -18.0952
22 C8y C 22.3035 -16.6924
23 C8y C 23.4958 -15.9911
24 N5x N 23.4958 -14.5884
25 C8x C 22.3035 -13.8870
26 C8x C 21.1112 -14.5884
27 N1b N 24.6881 -16.6924 #-
28 S4a S 25.9506 -15.9911
29 N1b N 27.1429 -16.6924
30 C1a C 28.3352 -15.9911
31 X F 22.3035 -18.0952
32 O3c O 25.2492 -14.7988
33 O3c O 26.6519 -14.7988
34 Z K 24.7800 -18.6200 #+
BOND 36
1 1 2 2
2 2 3 1
3 3 4 2
4 4 5 1
5 5 6 2
6 1 6 1
7 5 7 1
8 7 8 1
9 8 9 2
10 9 10 1
11 10 11 2
12 11 12 1
13 12 13 2
14 8 13 1
15 11 14 1
16 14 15 2
17 15 16 1
18 16 17 1
19 12 17 1
20 15 18 1
21 18 19 1
22 16 20 2
23 14 21 1
24 19 22 2
25 22 23 1
26 23 24 2
27 24 25 1
28 25 26 2
29 19 26 1
30 23 27 1
31 27 28 1
32 28 29 1
33 29 30 1
34 22 31 1
35 28 32 2
36 28 33 2
|